
-
Amgen NasdaqGS:AMGN Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Location: One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, United States | Website: https://www.amgen.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
201B
Cash
8.81B
Avg Qtr Burn
N/A
Short % of Float
2.68%
Insider Ownership
0.22%
Institutional Own.
83.59%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Uplizna® (inebilizumab-cdon) Details Inflammatory disease | Approved Quarterly sales | |
KRYSTEXXA Details Chronic refractory gout | Approved Quarterly sales | |
BLINCYTO® (blinatumomab) Details B-cell acute lymphoblastic leukemia | Approved Quarterly sales | |
BLINCYTO® (blinatumomab) Details B-cell acute lymphoblastic leukemia | Approved Quarterly sales | |
UPLIZNA (Inebilizumab-cdon) Details IgG4-related disease | Approved Quarterly sales | |
LUMAKRAS® (sotorasib) + Vectibix® (panitumumab) Details Colorectal cancer , Cancer, Metastatic colorectal cancer | Approved Quarterly sales | |
TEPEZZA Details Thyroid Eye Disease , Eye disease | Approved Quarterly sales | |
TAVNEOS (Avacopan) (C5aR) Details ANCA-Associated Vasculitis, Autoimmune disease | Approved Quarterly sales | |
IMDELLTRA (Tarlatamab) (AMG 757) Details Lung cancer, Cancer, Small cell lung cancer | Approved Quarterly sales | |
IMDELLTRA (Tarlatamab) (AMG 757) Details Cancer, Lung Cancer, Small cell lung cancer | Phase 3 Data readout | |
Olpasiran (AMG 890) Details Atherosclerotic cardiovascular disease | Phase 3 Data readout | |
Bemarituzumab Details Gastric cancer | Phase 3 Data readout | |
UPLIZNA (Inebilizumab-cdon) Details Neuromuscular disease, Myasthenia gravis | Phase 3 Data readout | |
Nplate® Details Chemo-induced thrombocytopenia | Phase 3 Data readout | |
TEZSPIRE Details Chronic rhinosinusitis with nasal polyps | Phase 3 Data readout | |
Rocatinlimab Details Atopic dermatitis | Phase 3 Data readout | |
LUMAKRAS® (sotorasib) Details Non-small cell lung carcinoma | Phase 3 Data readout | |
TAVNEOS (Avacopan) (C5aR) Details Skin disease/disorder, Hidradenitis suppurativa | Phase 3 Update | |
BLINCYTO® (blinatumomab) + Low intensity chemo Details B-cell acute lymphoblastic leukemia | Phase 3 Update | |
Phase 3 Initiation | ||
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Autoimmune disease, Cellulite | Phase 3 Initiation | |
Fipaxalparant (AMG 670) (HZN-825) Details Idiopathic pulmonary fibrosis | Phase 2b Data readout | |
Bempikibart (ADX-914) Details Alopecia areata | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Cutaneous lupus erythematosus | Phase 2 Data readout | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details Kidney transplantation, Kidney disease | Phase 2 Data readout | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Kidney transplantation, Kidney disease | Phase 2 Data readout | |
Dazodalibep (HZN-4920) Details Kidney disease, Lupus nephritis, Autoimmune disease | Phase 2 Data readout | |
Bempikibart (ADX-914) Details Atopic dermatitis | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Alopecia areata | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Systemic lupus erythematosus | Phase 2 Update | |
TAVNEOS (Avacopan) (C5aR) Details Kidney disease, C3 Glomerulopathy | Phase 2 Update | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Arthritis, Congenital adrenal hyperplasia, Genetic disorder, Autoimmune disease, Rheumatoid arthritis | Phase 2 Update | |
Tezspire Details Chronic obstructive pulmonary disease | Phase 2a Update | |
LUMAKRAS® (sotorasib) + Vectibix® (panitumumab) and FOLFIRI Details Colorectal cancer , Cancer | Phase 1b Data readout | |
IMDELLTRA (Tarlatamab) (AMG 757) + PD-L1 inhibitor Details Small cell lung cancer, Lung cancer, Cancer | Phase 1b Update | |
HZN-457 Details Chronic refractory gout | Phase 1 Data readout | |
AMG 193 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
Xaluritamig Details Cancer, Castration-resistant prostate cancer | Phase 1 Data readout | |
AMG 786 Details Obesity | Phase 1 Update |